
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14213983
[patent_doc_number] => 20190119376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-25
[patent_title] => ANTI-TIGIT ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 15/994583
[patent_app_country] => US
[patent_app_date] => 2018-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15994583
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/994583 | ANTI-TIGIT ANTIBODIES AND METHODS OF USE | May 30, 2018 | Abandoned |
Array
(
[id] => 13566357
[patent_doc_number] => 20180334726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-22
[patent_title] => SOMATIC MUTATIONS IN ATRX IN BRAIN CANCER
[patent_app_type] => utility
[patent_app_number] => 15/989820
[patent_app_country] => US
[patent_app_date] => 2018-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4515
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15989820
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/989820 | Somatic mutations in ATRX in brain cancer | May 24, 2018 | Issued |
Array
(
[id] => 13607023
[patent_doc_number] => 20180355060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-13
[patent_title] => Anti-Transglutaminase 2 Antibodies
[patent_app_type] => utility
[patent_app_number] => 15/987611
[patent_app_country] => US
[patent_app_date] => 2018-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15987611
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/987611 | Anti-transglutaminase 2 antibodies | May 22, 2018 | Issued |
Array
(
[id] => 18414177
[patent_doc_number] => 11668715
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Biomarkers of disease
[patent_app_type] => utility
[patent_app_number] => 16/615687
[patent_app_country] => US
[patent_app_date] => 2018-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 17345
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 207
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615687
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/615687 | Biomarkers of disease | May 21, 2018 | Issued |
Array
(
[id] => 15866337
[patent_doc_number] => 20200140572
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => CONDITIONAL INTERNALIZATION OF PEGYLATED AGENTS BY PRETARGETING BI-SPECIFIC PEG-BINDING ANTIBODIES FOR DIAGNOSIS AND THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/615822
[patent_app_country] => US
[patent_app_date] => 2018-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615822
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/615822 | CONDITIONAL INTERNALIZATION OF PEGYLATED AGENTS BY PRETARGETING BI-SPECIFIC PEG-BINDING ANTIBODIES FOR DIAGNOSIS AND THERAPY | May 8, 2018 | Abandoned |
Array
(
[id] => 14326569
[patent_doc_number] => 10294288
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-05-21
[patent_title] => Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 15/965305
[patent_app_country] => US
[patent_app_date] => 2018-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 31
[patent_no_of_words] => 52398
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965305
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/965305 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | Apr 26, 2018 | Issued |
Array
(
[id] => 16429494
[patent_doc_number] => 10829561
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-10
[patent_title] => Antibodies targeting quiescin sulfhydryl oxidase (QSOX1) and uses of same
[patent_app_type] => utility
[patent_app_number] => 15/961928
[patent_app_country] => US
[patent_app_date] => 2018-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 48
[patent_no_of_words] => 23120
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961928
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/961928 | Antibodies targeting quiescin sulfhydryl oxidase (QSOX1) and uses of same | Apr 24, 2018 | Issued |
Array
(
[id] => 17587726
[patent_doc_number] => 11325982
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Biparatopic and multiparatopic antibodies with common light chain and method of use
[patent_app_type] => utility
[patent_app_number] => 16/603711
[patent_app_country] => US
[patent_app_date] => 2018-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 21
[patent_no_of_words] => 12686
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 155
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603711
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/603711 | Biparatopic and multiparatopic antibodies with common light chain and method of use | Apr 8, 2018 | Issued |
Array
(
[id] => 16176970
[patent_doc_number] => 20200223938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => ANTIBODY FC VARIANTS FOR INCREASED BLOOD HALF-LIFE
[patent_app_type] => utility
[patent_app_number] => 16/603273
[patent_app_country] => US
[patent_app_date] => 2018-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603273
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/603273 | Antibody Fc variants for increased blood half-life | Apr 5, 2018 | Issued |
Array
(
[id] => 15831987
[patent_doc_number] => 20200131275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3
[patent_app_type] => utility
[patent_app_number] => 16/494566
[patent_app_country] => US
[patent_app_date] => 2018-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494566
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/494566 | MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3 | Mar 26, 2018 | Abandoned |
Array
(
[id] => 16799093
[patent_doc_number] => 10994008
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-04
[patent_title] => Modulation of tumor immunity
[patent_app_type] => utility
[patent_app_number] => 15/926035
[patent_app_country] => US
[patent_app_date] => 2018-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 28
[patent_no_of_words] => 14382
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 176
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15926035
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/926035 | Modulation of tumor immunity | Mar 19, 2018 | Issued |
Array
(
[id] => 19731134
[patent_doc_number] => 12209125
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Targeted gene integration of NK inhibitors genes for improved immune cells therapy
[patent_app_type] => utility
[patent_app_number] => 16/755082
[patent_app_country] => US
[patent_app_date] => 2018-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 39
[patent_no_of_words] => 35414
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755082
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/755082 | Targeted gene integration of NK inhibitors genes for improved immune cells therapy | Mar 8, 2018 | Issued |
Array
(
[id] => 16461101
[patent_doc_number] => 10844437
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-24
[patent_title] => Biomarkers for radiation treatment
[patent_app_type] => utility
[patent_app_number] => 15/913633
[patent_app_country] => US
[patent_app_date] => 2018-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 12939
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913633
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/913633 | Biomarkers for radiation treatment | Mar 5, 2018 | Issued |
Array
(
[id] => 13413203
[patent_doc_number] => 20180258144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-13
[patent_title] => CYTOTOXIC PROTEINS COMPRISING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILLING OF SPECIFIC CELL TYPES
[patent_app_type] => utility
[patent_app_number] => 15/899428
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27299
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15899428
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/899428 | CYTOTOXIC PROTEINS COMPRISING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILLING OF SPECIFIC CELL TYPES | Feb 19, 2018 | Abandoned |
Array
(
[id] => 13051553
[patent_doc_number] => 10047158
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-08-14
[patent_title] => Anti-TIGIT antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 15/895741
[patent_app_country] => US
[patent_app_date] => 2018-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 68726
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895741
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/895741 | Anti-TIGIT antibodies and methods of use | Feb 12, 2018 | Issued |
Array
(
[id] => 13457925
[patent_doc_number] => 20180280505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 15/885040
[patent_app_country] => US
[patent_app_date] => 2018-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15885040
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/885040 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS | Jan 30, 2018 | Abandoned |
Array
(
[id] => 13826645
[patent_doc_number] => 20190016807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
[patent_app_type] => utility
[patent_app_number] => 15/881611
[patent_app_country] => US
[patent_app_date] => 2018-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15881611
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/881611 | ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE | Jan 25, 2018 | Abandoned |
Array
(
[id] => 15191337
[patent_doc_number] => 10493139
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-03
[patent_title] => Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
[patent_app_type] => utility
[patent_app_number] => 15/876538
[patent_app_country] => US
[patent_app_date] => 2018-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 14178
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876538
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/876538 | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor | Jan 21, 2018 | Issued |
Array
(
[id] => 13386397
[patent_doc_number] => 20180244740
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => BH3 PEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/869537
[patent_app_country] => US
[patent_app_date] => 2018-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15869537
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/869537 | BH3 peptides and methods of use thereof | Jan 11, 2018 | Issued |
Array
(
[id] => 13369051
[patent_doc_number] => 20180236066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-23
[patent_title] => METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 15/866325
[patent_app_country] => US
[patent_app_date] => 2018-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18646
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866325
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/866325 | METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS | Jan 8, 2018 | Abandoned |